Project description:A Cartes d'Identite des Tumeurs (CIT) project from the French National League Against Cancer (http://cit.ligue-cancer.net ) 25 glioblastoma multiforme tumors hybridized on Illumina SNP and Affymetrix gene expression arrays. Project leader : François DUCRAY (francois.ducray@chu-lyon.fr). CIT Analysis : Julien LAFFAIRE (laffairej@ligue-cancer.net). Note: PFS : progression-free survival, OS: Overall Survival,BCNU : Carmustine (chemotherapy agent). RESPONDER: if the patient has shown or not shown a response to the treatment (Bevacizumab (Avastin) plus Irinotecan). Progression during : If the disease has progressed (cancer relapse or patient's death); otherwise (patient is alive without relapse).
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
Project description:We used methylation DNA arrays to observe the genomic wild methylation profiles in 31 malignant ovarian tumors. After validations, we selected, NEFH and HS3ST2. We used bisulfite pyrosequencing to expose methylation status for 84 independent samples. Kaplan–Meier survival and Cox regression analysis estimates the association with ovarian cancer outcome. We discovered patients with high methyatlion of two genes, had a shorter median 5-years overall survival. We also evaluated the high-methylation of a panel genes in patients, that presented as an independat factor for associated with poor outcomes. High-methylation of NEFH and HS3ST2 are provided the prognostic index for the poor outcome of overall survival in ovarian cancers.
